Literature DB >> 28110473

How Presentation of Drug Detection Results Changed Reports of Product Adherence in South Africa, Uganda and Zimbabwe.

Petina Musara1, Elizabeth T Montgomery2, Nyaradzo M Mgodi3, Kubashni Woeber4, Carolyne A Akello5, Miriam Hartmann2, Helen Cheng2, Lisa Levy6, Ariana Katz2, Cynthia I Grossman7, Z Mike Chirenje3, Ariane van der Straten2,8, Barbara Mensch9.   

Abstract

Accurate estimates of study product use are critical to understanding and addressing adherence challenges in HIV prevention trials. The VOICE trial exposed a significant gap between self-reported adherence and drug detection. The VOICE-D qualitative study was designed to better understand non-adherence during VOICE, and was conducted in 2 stages: before (stage 1) and after (stage 2) drug detection results were provided to participants. Transcripts from 44 women who participated in both stages were analysed to understand the effect of presenting drug detection data on narratives of product use. Thirty-six women reported high adherence in stage 1, yet admitted non-use in stage 2, three reported high adherence in both stages (contrary to their drug detection results) and five had consistent responses across both stages and drug results. Presenting objective measures of use may facilitate more accurate product use reporting and should be evaluated in future prevention trials.

Entities:  

Keywords:  Adherence measures; Drug detection results; HIV prevention; Microbicides; Pre-exposure prophylaxis

Mesh：

Substances：

Year:  2018        PMID： 28110473      PMCID： PMC5587392          DOI： 10.1007/s10461-017-1685-x

Source DB:  PubMed          Journal:  AIDS Behav        ISSN： 1090-7165


  18 in total

1.  Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Authors:  Quarraisha Abdool Karim; Salim S Abdool Karim; Janet A Frohlich; Anneke C Grobler; Cheryl Baxter; Leila E Mansoor; Ayesha B M Kharsany; Sengeziwe Sibeko; Koleka P Mlisana; Zaheen Omar; Tanuja N Gengiah; Silvia Maarschalk; Natasha Arulappan; Mukelisiwe Mlotshwa; Lynn Morris; Douglas Taylor
Journal:  Science       Date:  2010-07-19       Impact factor: 47.728

2.  Acceptability of drug detection monitoring among participants in an open-label pre-exposure prophylaxis study.

Authors:  Kimberly A Koester; Albert Liu; Christopher Eden; K Rivet Amico; Vanessa McMahan; Pedro Goicochea; Sybil Hosek; Kenneth H Mayer; Robert M Grant
Journal:  AIDS Care       Date:  2015-05-22

Review 3.  Microbicides and their potential as a catalyst for multipurpose sexual and reproductive health technologies.

Authors:  Q Abdool Karim; C Baxter; S Abdool Karim
Journal:  BJOG       Date:  2014-10       Impact factor: 6.531

4.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

Authors:  Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

5.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.

Authors:  Jared M Baeten; Deborah Donnell; Patrick Ndase; Nelly R Mugo; James D Campbell; Jonathan Wangisi; Jordan W Tappero; Elizabeth A Bukusi; Craig R Cohen; Elly Katabira; Allan Ronald; Elioda Tumwesigye; Edwin Were; Kenneth H Fife; James Kiarie; Carey Farquhar; Grace John-Stewart; Aloysious Kakia; Josephine Odoyo; Akasiima Mucunguzi; Edith Nakku-Joloba; Rogers Twesigye; Kenneth Ngure; Cosmas Apaka; Harrison Tamooh; Fridah Gabona; Andrew Mujugira; Dana Panteleeff; Katherine K Thomas; Lara Kidoguchi; Meighan Krows; Jennifer Revall; Susan Morrison; Harald Haugen; Mira Emmanuel-Ogier; Lisa Ondrejcek; Robert W Coombs; Lisa Frenkel; Craig Hendrix; Namandjé N Bumpus; David Bangsberg; Jessica E Haberer; Wendy S Stevens; Jairam R Lingappa; Connie Celum
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

6.  The science of being a study participant: FEM-PrEP participants' explanations for overreporting adherence to the study pills and for the whereabouts of unused pills.

Authors:  Amy L Corneli; Kevin McKenna; Brian Perry; Khatija Ahmed; Kawango Agot; Fulufhelo Malamatsho; Joseph Skhosana; Jacob Odhiambo; Lut Van Damme
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

7.  Disclosure of pharmacokinetic drug results to understand nonadherence.

Authors:  Ariane van der Straten; Elizabeth T Montgomery; Petina Musara; Juliane Etima; Sarita Naidoo; Nicole Laborde; Miriam Hartmann; Lisa Levy; Thola Bennie; Helen Cheng; Jeanna Piper; Cynthia I Grossman; Jeanne Marrazzo; Barbara Mensch
Journal:  AIDS       Date:  2015-10-23       Impact factor: 4.177

8.  Preexposure prophylaxis for HIV infection among African women.

Authors:  Lut Van Damme; Amy Corneli; Khatija Ahmed; Kawango Agot; Johan Lombaard; Saidi Kapiga; Mookho Malahleha; Fredrick Owino; Rachel Manongi; Jacob Onyango; Lucky Temu; Modie Constance Monedi; Paul Mak'Oketch; Mankalimeng Makanda; Ilse Reblin; Shumani Elsie Makatu; Lisa Saylor; Haddie Kiernan; Stella Kirkendale; Christina Wong; Robert Grant; Angela Kashuba; Kavita Nanda; Justin Mandala; Katrien Fransen; Jennifer Deese; Tania Crucitti; Timothy D Mastro; Douglas Taylor
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

9.  Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTN-003 (VOICE) study.

Authors:  Ariane van der Straten; Elizabeth R Brown; Jeanne M Marrazzo; Michael Z Chirenje; Karen Liu; Kailazarid Gomez; Mark A Marzinke; Jeanna M Piper; Craig W Hendrix
Journal:  J Int AIDS Soc       Date:  2016-02-04       Impact factor: 5.396

10.  MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments.

Authors:  Craig W Hendrix; Beatrice A Chen; Vijayanand Guddera; Craig Hoesley; Jessica Justman; Clemensia Nakabiito; Robert Salata; Lydia Soto-Torres; Karen Patterson; Alexandra M Minnis; Sharavi Gandham; Kailazarid Gomez; Barbra A Richardson; Namandje N Bumpus
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240
View more
  5 in total

1.  Women's experience receiving drug feedback and adherence counseling in MTN-025/HOPE - an HIV Prevention open-label trial of the Dapivirine Vaginal Ring.

Authors:  Ariana Wendy Keel Katz; Iván C Balán; Krishnaveni Reddy; Juliane Etima; Kubashni Weber; Thelma Tauya; Millicent Atujuna; Rachel Scheckter; Kenneth Ngure; Lydia Soto-Torres; Nyaradzo Mgodi; Thesla Palanee-Phillips; Jared M Baeten; Ariane van der Straten
Journal:  AIDS Behav       Date:  2022-05-10

2.  Brief Report: Validation of a Urine Tenofovir Immunoassay for Adherence Monitoring to PrEP and ART and Establishing the Cutoff for a Point-of-Care Test.

Authors:  Monica Gandhi; Peter Bacchetti; Matthew A Spinelli; Hideaki Okochi; Jared M Baeten; Oraphan Siriprakaisil; Virat Klinbuayaem; Warren C Rodrigues; Guohong Wang; Michael Vincent; Tim R Cressey; Paul K Drain
Journal:  J Acquir Immune Defic Syndr       Date:  2019-05-01       Impact factor: 3.731

3.  Debrief Reports to Expedite the Impact of Qualitative Research: Do They Accurately Capture Data from In-depth Interviews?

Authors:  Jane M Simoni; Kristin Beima-Sofie; K Rivet Amico; Sybil G Hosek; Mallory O Johnson; Barbara S Mensch
Journal:  AIDS Behav       Date:  2019-08

4.  Client-Centered Adherence Counseling with Adherence Measurement Feedback to Support Use of the Dapivirine Ring in MTN-025 (The HOPE Study).

Authors:  Iván C Balán; Rebecca Giguere; Cody Lentz; Bryan A Kutner; Clare Kajura-Manyindo; Rose Byogero; Florence Biira Asiimwe; Yvonne Makala; Jane Jambaya; Nombuso Khanyile; Diane Chetty; Lydia Soto-Torres; Ashley Mayo; Nyaradzo M Mgodi; Thesla Palanee-Phillips; Jared M Baeten
Journal:  AIDS Behav       Date:  2021-02

5.  Understanding women's motivations to participate in MTN-003/VOICE, a phase 2b HIV prevention trial with low adherence.

Authors:  Ariana W K Katz; Barbara S Mensch; Kubashni Woeber; Petina Musara; Juliane Etima; Ariane van der Straten
Journal:  BMC Womens Health       Date:  2019-01-25       Impact factor: 2.809
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.